VERIGRAFT Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $12.1M

  • Investors
  • 4

VERIGRAFT General Information

Description

Developer of personalized tissue engineered human grafts designed for transplantation and tissue replacement purposes. The company's platform applies decellularised donated human tissues combined with patient-derived cells, standardized GMP compliant manufacturing processes, immune compatibility matching, and quality controlled biological scaffolds to produce individualized veins, arteries, and other soft tissues, enabling hospitals, transplant centers, and clinical researchers to address vascular and tissue repair needs while reducing immune rejection risk and long-term dependence on immunosuppressive therapies.

Contact Information

Website
www.verigraft.com
Formerly Known As
NovaHep
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden
+46 070-597
Primary Industry
Biotechnology
Parent Company
Flask
Vertical(s)
Life Sciences
Corporate Office
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden
+46 070-597

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VERIGRAFT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 12-Mar-2026 $12.1M Completed Clinical Trials - Phase 1
10. Equity Crowdfunding 14-Mar-2025 Completed Clinical Trials - Phase 1
9. Grant 14-Feb-2025 Completed Clinical Trials - Phase 1
8. Later Stage VC 01-Jan-2025 Completed Generating Revenue
7. Later Stage VC 03-Mar-2022 Completed Clinical Trials - Phase 1
6. Later Stage VC 28-Jan-2021 Completed Clinical Trials - Phase 1
5. Later Stage VC 01-Jan-2018 Completed Startup
4. Grant 18-May-2017 Completed Clinical Trials - Phase 1
3. Merger/Acquisition 01-Jan-2015 Completed Clinical Trials - Phase 1
2. Secondary Transaction - Private 25-Aug-2011 Completed Clinical Trials - Phase 1
To view VERIGRAFT’s complete valuation and funding history, request access »

VERIGRAFT Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 49,943 $6.41 $6.41 1x $6.41 4.83%
Ordinary 108,155 $14.43 $14.43 1x $14.43 10.46%
To view VERIGRAFT’s complete cap table history, request access »

VERIGRAFT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of personalized tissue engineered human grafts designed for transplantation and tissue replacement purposes. T
Biotechnology
Gothenburg, Sweden
18 As of 2026

Alachua, FL
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VERIGRAFT Competitors (3)

One of VERIGRAFT’s 3 competitors is Axogen, a Formerly VC-backed company based in Alachua, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axogen Formerly VC-backed Alachua, FL
Humacyte Formerly VC-backed Durham, NC
enVVeno Medical Formerly PE-Backed Irvine, CA
You’re viewing 3 of 3 competitors. Get the full list »

VERIGRAFT Patents

  • 73

    Total Documents Applications and Grants

  • Total Patents Families

  • 39

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

VERIGRAFT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4683685-A1 Nerve grafts for peripheral nerve regeneration Pending 21-Mar-2023
US-20240342342-A1 Nerve grafts for peripheral nerve regeneration Pending 21-Mar-2023
WO-2024194817-A1 Nerve grafts for peripheral nerve regeneration Inactive 21-Mar-2023
ES-2953744-T3 Custom blood vessel preparation methods Active 03-Aug-2018
ES-2988106-T3 Customized blood vessel preparation methods Active 03-Aug-2018 A61L27/507
To view VERIGRAFT’s complete patent history, request access »

VERIGRAFT Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VERIGRAFT Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alden Impact Capital Venture Capital Minority
Allenex Corporation Minority
To view VERIGRAFT’s complete investors history, request access »

Ready to get started?

Request a free trial

VERIGRAFT FAQs

  • When was VERIGRAFT founded?

    VERIGRAFT was founded in 2004.

  • Where is VERIGRAFT headquartered?

    VERIGRAFT is headquartered in Gothenburg, Sweden.

  • What is the size of VERIGRAFT?

    VERIGRAFT has 18 total employees.

  • What industry is VERIGRAFT in?

    VERIGRAFT’s primary industry is Biotechnology.

  • Is VERIGRAFT a private or public company?

    VERIGRAFT is a Private company.

  • What is VERIGRAFT’s current revenue?

    The current revenue for VERIGRAFT is .

  • How much funding has VERIGRAFT raised over time?

    VERIGRAFT has raised $27.7M.

  • Who are VERIGRAFT’s investors?

    Alden Impact Capital and Allenex have invested in VERIGRAFT.

  • Who are VERIGRAFT’s competitors?

    Axogen, Humacyte, and enVVeno Medical are competitors of VERIGRAFT.

  • When was VERIGRAFT acquired?

    VERIGRAFT was acquired on 12-Mar-2026.

  • Who acquired VERIGRAFT?

    VERIGRAFT was acquired by Flask.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process